HN2002000355A - Combinacion farmaceutica - Google Patents

Combinacion farmaceutica

Info

Publication number
HN2002000355A
HN2002000355A HN2002000355A HN2002000355A HN2002000355A HN 2002000355 A HN2002000355 A HN 2002000355A HN 2002000355 A HN2002000355 A HN 2002000355A HN 2002000355 A HN2002000355 A HN 2002000355A HN 2002000355 A HN2002000355 A HN 2002000355A
Authority
HN
Honduras
Prior art keywords
pharmaceutical combination
combination
receiver agonist
agonist
dipositives
Prior art date
Application number
HN2002000355A
Other languages
English (en)
Inventor
Michael Yeadon
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of HN2002000355A publication Critical patent/HN2002000355A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Abstract

LA PRESENTE INVENCION SE REFIERE A UNA COMBINACION INHALADA DE UN AGONISTA DEL RECEPTOR DE ADENOSINA A2a Y UN AGONISTA DEL RECEPTOR B2-ADRENERGICO, A COMPOSICIONES FARMACEUTICAS, INCLUYENDO LOS DIPOSITIVOS PARA LA ADMINISTRACION Y A LOS USOS DE DICHA COMBINACION.
HN2002000355A 2001-12-07 2002-12-05 Combinacion farmaceutica HN2002000355A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0129397.6A GB0129397D0 (en) 2001-12-07 2001-12-07 Pharmaceutical combination

Publications (1)

Publication Number Publication Date
HN2002000355A true HN2002000355A (es) 2003-02-21

Family

ID=9927249

Family Applications (1)

Application Number Title Priority Date Filing Date
HN2002000355A HN2002000355A (es) 2001-12-07 2002-12-05 Combinacion farmaceutica

Country Status (12)

Country Link
US (1) US20030109485A1 (es)
AR (1) AR037709A1 (es)
AU (1) AU2002347532A1 (es)
GB (1) GB0129397D0 (es)
GT (1) GT200200261A (es)
HN (1) HN2002000355A (es)
PA (1) PA8560401A1 (es)
PE (1) PE20030835A1 (es)
SV (1) SV2004001429A (es)
TW (1) TW200303754A (es)
UY (1) UY27565A1 (es)
WO (1) WO2003047628A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8455437B2 (en) * 2005-02-04 2013-06-04 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Method to predict and prevent oxygen-induced inflammatory tissue injury
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US10149823B2 (en) 2013-04-30 2018-12-11 Otitopic Inc. Dry powder formulations and methods of use
US10195147B1 (en) 2017-09-22 2019-02-05 Otitopic Inc. Dry powder compositions with magnesium stearate
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AP979A (en) * 1995-04-14 2001-06-28 Glaxo Wellcome Inc Metered dose imhaler for salmeterol.
GB9913932D0 (en) * 1999-06-15 1999-08-18 Pfizer Ltd Purine derivatives
GB0003960D0 (en) * 2000-02-18 2000-04-12 Pfizer Ltd Purine derivatives

Also Published As

Publication number Publication date
WO2003047628A1 (en) 2003-06-12
TW200303754A (en) 2003-09-16
US20030109485A1 (en) 2003-06-12
GT200200261A (es) 2003-07-11
PA8560401A1 (es) 2003-12-10
UY27565A1 (es) 2003-07-31
AU2002347532A1 (en) 2003-06-17
SV2004001429A (es) 2004-05-07
AR037709A1 (es) 2004-12-01
GB0129397D0 (en) 2002-01-30
PE20030835A1 (es) 2003-10-08

Similar Documents

Publication Publication Date Title
CL2004000745A1 (es) Composicion farmaceutica solida para administracion oral que comprende un agonista del receptor s1p y un alcohol de azucar.
PA8521001A1 (es) Derivados de purina
PA8503601A1 (es) Derivados de purina
HN2001000027A (es) Derivados de purina
HN2004000538A (es) "PIRIDO[ 2,3-d ] PIRIMIDINA-2,4-DIAMINAS COMO-INHIBIDORES DE PDE 2"
HN2000000204A (es) Derivados de la purina
HN2002000266A (es) Preparacion y uso de derivados de imidazol para el tratamiento de la obesidad.
UY28766A1 (es) Compuestos heteropolicíclicos adicionales y su uso como antagonistas del receptor de glutamato metabotrópico
EA200701065A1 (ru) Инъецируемые составы, содержащие нанодисперсный оланзапин
UY30460A1 (es) Compuestos terapéuticos
MY129263A (en) Vaccine composition
UY28001A1 (es) Derivados de azol-pirimidina condensados
HN2003000417A (es) Intermedio de formulacion aceptablemente no higroscopico que comprende un farmaco higroscopico
CL2008002207A1 (es) Composicion farmaceutica que comprende inmunosupresores para la mejora del efecto en el uso de un antagonista de interleucina-6 (il-6) para el tratamiento de enfermedades relacionadas con il-6 (div. sol. 896-04).
EE200300033A (et) Tsüklopentanoindoolid, nende kasutamine ravimi valmistamiseks ning neid sisaldav farmatseutiline kompositsioon
CR8371A (es) Formulaciones de medicamento que contienen saborizantes con mejores propiedades farmaceuticas
UY27188A1 (es) Uso de agonistas inversos de gabaa en combinación con agonistas parciales del receptor de nicotina, estrógenos, moduladores selectivos de estrógenos o vitamina e, para el tratamiento de trastornos cognitivos.
AR034213A1 (es) Composiciones de medicamentos sobre la base de agentes anticolinergicos e inhibidores de pde-iv
CY1111567T1 (el) Ενδιαμεσα διβενζο (b,f) αζεπινης
ECSP066860A (es) Formulaciones de matriz oral que comprenden licarbazepina
HN2002000355A (es) Combinacion farmaceutica
HN2002000348A (es) Combinacion farmaceutica
AR030378A1 (es) Empleo de triazintrion-sulfonas para la lucha contra la coccidiosis
PA8567701A1 (es) Agonistas del receptor b3-adrenergico
PA8496801A1 (es) Complejo farmaceutico